Full Text View
Tabular View
No Study Results Posted
Related Studies
Metabolic Abnormalities in Children With Epilepsy
This study has been completed.
Study NCT00001325   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: March 3, 2008   History of Changes

November 3, 1999
March 3, 2008
April 1992
 
 
 
Complete list of historical versions of study NCT00001325 on ClinicalTrials.gov Archive Site
 
 
 
Metabolic Abnormalities in Children With Epilepsy
Natural History of Metabolic Abnormalities in Children With Epilepsy

This study is designed to use positron emission tomography to measure brain energy use. Positron Emission Tomography (PET) is a technique used to investigate the functional activity of the brain. The PET technique allows doctors to study the normal processes of the brain (central nervous system) of normal individuals and patients with neurologic illnesses without physical / structural damage to the brain.

When a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and water. Blood carries fuel to the brain and waste products away from the brain. As brain activity increases blood flow to and from the area of activity increases also.

Researchers can label a sugar with a small radioactive molecule called FDG (fluorodeoxyglucose). As areas of the brain use more sugar the PET scan will detect the FDG and show the areas of the brain that are active. By using this technique researchers hope to answer the following questions;

4. Are changes in brain energy use (metabolism) present early in the course of epilepsy

5. Do changes in brain metabolism match the severity of patient's seizures

6. Do changes in metabolism occur over time or in response to drug therapy

We propose to study children with recent onset partial epilepsy, cryptogenic infantile spasms, and idiopathic Lennox-Gastaut Syndrome with serial FDG-PET to elucidate the natural history and evolution of metabolic abnormalities associated with such epilepsies. The severity of the seizure disorder, and cognitive impairment, when present, will be correlated with the presence and extent of focal and global cerebral metabolic abnormalities.

 
Observational
 
  • Generalized Epilepsy
  • Infantile Spasms
  • Metabolic Disease
  • Partial Epilepsy
  • Seizures
Drug: 18 FDG
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
80
June 2004
 

INCLUSION CRITERIA:

Patients with partial seizures, infantile spasms and Lennox-Gastaut syndrome will be selected.

EXCLUSION CRITERIA:

Evidence of a structural lesion as cause for epilepsy.

Degenerative or metabolic disease.

Inability to comply with the protocol.

Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00001325
 
920175, 92-N-0175
National Institute of Neurological Disorders and Stroke (NINDS)
 
 
National Institutes of Health Clinical Center (CC)
June 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP